115450 — HLB Therapeutics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for HLB Therapeutics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	43,586	42,403	52,591	54,932	69,561
Cost of Revenue
Gross Profit	5,133	8,819	7,359	10,201	10,172
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	59,955	50,349	60,629	70,594	76,530
Operating Profit	-16,368	-7,946	-8,038	-15,662	-6,968
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-17,764	-11,573	-2,965	-22,926	-11,086
Provision for Income Taxes
Net Income After Taxes	-17,764	-11,573	-2,965	-22,926	-9,668
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-17,197	-11,354	-2,302	-22,793	-9,227
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-17,197	-11,354	-2,302	-22,793	-9,227
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-185	-142	-35.2	-163	-77.3
Dividends per Share